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Contributing Factors to Diabetic Brain Injury and
Cognitive Decline
Nirmal Verma1, Florin Despa1,2
Departments of 1Pharmacology and Nutritional Sciences, 2Neurology, College of Medicine, University of Kentucky, Lexington, KY, USA

The link of diabetes with co-occurring disorders in the brain involves complex and multifactorial pathways. Genetically engineered
rodents that express familial Alzheimer’s disease-associated mutant forms of amyloid precursor protein and presenilin 1 (PSEN1)
genes provided invaluable insights into the mechanisms and consequences of amyloid deposition in the brain. Adding diabetes factors (obesity, insulin impairment) to these animal models to predict success in translation to clinic have proven useful at some extent only. Here, we focus on contributing factors to diabetic brain injury with the aim of identifying appropriate animal models that
can be used to mechanistically dissect the pathophysiology of diabetes-associated cognitive dysfunction and how diabetes medications may influence the development and progression of cognitive decline in humans with diabetes.
Keywords: Dementia; Diabetes mellitus; Obesity

INTRODUCTION
Type 2 diabetes mellitus accelerates age-related cognitive decline [1,2] and increases the risk for dementia [3-7]. Pathophysiological processes causing diabetic brain injury and cognitive decline begin years before actual manifestation of symptoms occurs [8,9]. Compared to cognitive impairment in individuals without diabetes, cognitive decline in humans with diabetes can be influenced by the type of diabetes (type 1 diabetes mellitus or type 2 diabetes mellitus), duration of diabetes,
antidiabetic medications and presence of other diabetic-related complications [10,11]. Here, we focus on contributing factors to diabetic brain injury with the aim of identifying appropriate animal models that can be used to mechanistically dissect the pathophysiology of diabetes-associated cognitive dysfunction and how diabetes medications may influence the development and progression of cognitive decline in humans
with diabetes.
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CONTRIBUTING FACTORS TO DIABETIC
BRAIN INJURY IN HUMANS
Common diabetes-associated pathological processes and complications that can have deleterious impact on brain function
are summarized in Fig. 1.
Hyperglycemia
Efficient delivery of glucose to brain cells is critical for brain
function [12]. Glucose uptake by the brain cells appears to be
independent of insulin; however neurons are known to express
receptors for insulin and insulin related peptide (insulin-like
growth factor 1 [IGF-1]) [12]. Both insulin and IGF-1 play important roles in neuronal development and affect cognition
[12]. Insulin resistance and consequent abnormal blood glucose levels as observed in type 2 diabetes mellitus can have
detrimental effects on brain and cognitive function [13,14].
Fluctuation in glucose levels or peaks, which is common in diabetes, increases the risk for cognitive decline. Targeting gluThis is an Open Access article distributed under the terms of the Creative Commons
Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/)
which permits unrestricted non-commercial use, distribution, and reproduction in any
medium, provided the original work is properly cited.
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Fig. 1. Risk factors for cognitive dysfunctions in diabetes. Figure showing main risk factors involved in cognitive dysfunction in diabetes. These risk factors may be associated with different types of cognitive dysfunction in diabetes.
cose peaks has been proposed as therapeutic strategy for prevention of diabetes-associated cognitive dysfunction [14]. In
laboratory animals, glucose lowering compounds such as metformin, thiazolidinediones and compounds targeting the glucagon like peptide-1 receptor have beneficial effects on cognition [10]. It was reported that agonists of peroxisome proliferator-activated receptor gamma (PPARγ), a ligand-activated
transcriptional factor, improved brain function in a rat model
of streptozotocin-induced diabetes [15]. Decreased activity of
PPARγ and its cofactor peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α) causes mitochondrial
dysfunction and oxidative stress in the settings of type 2 diabetes mellitus and in brain disorders. Glucose lowering thiazolidinediones, such as rosiglitazone and pioglitazone, act as agonist for PPARγ and improve cognitive function. Glucagon-like
peptide 1 (GLP-1) receptor agonists are known elicit neuroprotective effects in animal models of stroke, Alzheimer’s disease (AD) and Parkinson’s disease [16]. GLP-1 receptor agonists reduced neuro-inflammation and increased neuro-survival [16]. Metformin reduces tau hyper-phosphorylation by
inducing protein phosphatase 2A (PP2A) activity, a major tau
phosphatase [17].
http://e-dmj.org

Diabetes Metab J 2019;43:560-567

Dyslipidemia
Elevated levels of plasma triglycerides and cholesterol may play
a role in diabetes-associated risk for poor cognition function
[18,19]. Pharmacological interventions to ameliorate dyslipidemia may influence the progression of cognitive decline in individuals with diabetes and cerebrovascular disease [18,19].
Cholesterol modulates the activity of enzymes involved (β and
γ-secretases) in amyloid precursor protein (APP) processing
and thus it can affect production of amyloid β (Aβ) protein.
Because β and γ-secretases enzymes are membrane bound enzymes, the high cholesterol content in membrane lipid rafts
could facilitate clustering of these enzymes with their substrate,
thereby promoting cleavage of precursors of Aβ protein into
amyloidogenic forms [20].
Hypertension
Cerebrovascular complications in individuals with diabetes are
frequently linked to the presence of hypertension [21,22]. The
use of anti-hypertensive medications may diminish the risk of
dementia in diabetic patients by 4% to 24% [23]; however, the
underlying molecular mechanisms remain unknown [24].

561
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Inflammation and blood-brain barrier injury
Cerebrovascular accumulation of toxic lipids, advanced glycation end products (AGEs) and aggregated proteins trigger inflammatory responses and secretion of inflammatory mediators in the circulation [25-28]. Inflammatory responses are associated with blood-brain barrier (BBB) breakdown [29]. BBB
injury further exposes brain parenchyma to neurotoxic blood
proteins, thrombin, fibrin, plasmin, hemoglobin, and iron
from lysed red blood cells. A leaky BBB causes abnormal neuronal activity [29] that plays a role in diabetes-associated neurological deficits [30].
Chronically elevated levels of C-reactive proteins, interleukin
6 (IL-6), fibrinogen, and tumor necrosis factor α are strongly
correlated with cognitive decrement in diabetic patients [3134]. Reducing systemic inflammation promotes brain health
[31-34].
Vascular contributions to cognitive impairment and
dementia
Macrovascular disease such as myocardial infarction or stroke
negatively affects cognitive performance [8,35]. Microvascular
abnormalities are also frequent in patients with type 2 diabetes
mellitus [8,35]. Patients with diabetes and individuals with
normal metabolic function showing retinal microvascular abnormalities are at high risk of cognitive decline [36]. Due to
similarities between retina cells and cerebrovascular cells, retinopathy can be used as a marker and therapeutic target for microangiopathy and cerebral small vessel disease [37]. It is speculated that cerebral small vessel disease might be due to long
term endothelium dysfunction, capillary loss and subsequent
ischemia leading to white matter disease and neurological deficits [25,28,29]. White matter disease of vascular origin is commonly associated with vascular contributions to cognitive impairment and dementia (VCID) [25,28,29].
Vascular endothelial cell dysfunction is linked to vascular
accumulation of toxic lipids [26], AGEs [27] and aggregated
proteins [25]. Interaction of AGEs with endothelial cells increases generation of reactive oxygen species (ROS) [27] and
impairs the production of vasodilatory substances resulting in
a reduced cerebral blood flow [38]. Elevated ROS damage cellular structures and activate matrix metalloproteinases enzyme, which further induce cytoskeletal reorganization and
vascular remodeling [29]. Cytoskeletal reorganization increases the vascular permeability by disrupting tight junction proteins in endothelium, which increases energy depletion and al562

ters neural viability [29,38].
Systemic amylin dyshomeostasis
Amylin, or islet APP, is a pancreatic hormone that is synthesized and co-secreted with insulin by pancreatic β-cells and
participates in the central regulation of satiety [39]. Individuals
with pre-diabetic insulin resistance have hypersecretion of amylin (and insulin) leading to amylin oligomerization and pancreatic amylin amyloid. Amylin dyshomeostasis plays an important role in the development and progression of type 2 diabetes mellitus [39-41]. Deposits of amylin amyloid were detected in extra-pancreatic tissues, including the heart [42], kidneys [43] and the brain [44-48]. Because amylin amyloid is
toxic [39-41], the presence of amylin deposition in brains of
individuals with AD suggests that the development of drugs
that could limit amylin deposition in the brain may provide
benefit to patients with AD or mild cognitive impairment.
Calcium dysregulation in diabetes and dementia
Altered Ca2+ signaling contributes in brain dysfunction through
multiple mechanisms [49]. Erickson et al. [50], showed that diabetes causes Ca2+/calmodulin-dependent protein kinase II
(CaMKII) modification at Ser279 through o-linked N-acetylglucosamine (O-GlcNAc). This modification of CaMKII has
been detected both in hearts and brains of humans with type 2
diabetes mellitus [50].

DIABETIC INJURY IN LABORATORY
ANIMALS
Mouse and rat models for diabetes and AD are generated by
gene manipulation or/and pharmacological intervention (Table 1). In mice genetically modified to develop parenchymal
deposition of Aβ and intraneuronal accumulation of hyperphosphorylated tau, brain pathology and behavior changes are
accelerated by diabetic states induced by streptozotocin injection or by diet interventions [51-57]. Mice generated by crossing obese db/db mice with AD mice develop microhemorrhages and accelerated behavior changes compared to AD
mice [55].
Brain insulin resistance
Brain insulin resistance increases the activity of β-secretase
and γ-secretase [54,55] promoting cerebral Aβ deposition and
tau hyperphosphorylation [51-57]. Intracerebroventricular
Diabetes Metab J 2019;43:560-567
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Table 1. Diabetes and Alzheimer’s disease rodent models
Intervention

Pathophysiology

Non-AD mouse and rat models [50-53]
Sterptozotocin

Increase pTau pathology and altered hippocampal synaptic plasticity

Diet

Mild effect on central nervous system

Amylin dyshomeostasis

Vascular amylin oligomer deposition
Microhaemorrhages
Brain inflammation
Brain atrophy
Microglia activation
Parenchymal amylin plaques
Impaired synthesis of neurotransmitters

Leptin deficiency

Increased amyloid-β generation

Mouse and rat models of AD [50-53]
Sterptozotocin

Exacerbated brain amyloidosis
Neuro-inflammation and injury

Diet

Increased amyloid-β pathology

Leptin deficiency

Amyloid-β
Aneurisms
Small strokes

AD, Alzheimer’s disease; pTau, phosphorylated tau.

administration of insulin increased learning ability in normal
mice [58,59]; however, a similar treatment showed no significant effect on brain function in diabetic mice [59]. Cerebral
accumulation of Aβ and phosphorylation of tau in mice were
reduced by pharmacological interventions that ameliorate insulin resistance [60].
White matter disease
In a rat model for type 2 diabetes mellitus transgenic for human islet amyloid polypeptide (the HIP rat) [25], the development of diabetes is associated with amylin-mediated vascular
endothelial dysfunction leading to axonal demyelination,
white matter rarefaction and neurological deficits [25]. Phenylalanine and tyrosine, two main precursors of neurotransmitters, were greatly decreased in brains of diabetic HIP rats
compared to non-diabetic littermates [61]. These results [25,
61] indicate amylin dyshomeostasis as a direct molecular link
between pancreatic pathology in diabetes and VCID.
Peroxidative neuronal injury and neuroinflammation
In addition to amylin plaques and mixed amylin-Aβ deposits,
brains of diabetic patients with AD show amylin immunoreachttp://e-dmj.org
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tive deposits inside the neurons [62]. Neuronal amylin formed
adducts with 4-hydroxynonenal (4HNE), a marker of peroxidative membrane injury, and increased synthesis of the proinflammatory cytokine IL-1β [62]. These pathological changes
were mirrored in rats expressing human amylin in pancreatic
islets (HIP rats) and mice intravenously injected with aggregated human amylin, but not in hyperglycemic rats secreting
wild-type non-amyloidogenic rat amylin [62]. In cultured primary hippocampal rat neurons, aggregated amylin increased
IL-1β synthesis via membrane destabilization and subsequent
generation of 4HNE [62]. These effects were blocked by membrane stabilizers and lipid peroxidation inhibitors [62]. Thus,
elevated circulating levels of aggregated amylin negatively affect the neurons causing peroxidative membrane injury and
aberrant inflammatory responses independent of other confounding factors of diabetes. Schematic view of effect of amylin
dyshomeostasis on brain is shown in Fig. 2.

CONCLUSIONS
In conclusion, preclinical data and epidemiological studies
show a consistent association of diabetes with cognitive de563
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Fig. 2. Proposed mechanism underlying the impact of amylin dyshomeostasis on the brain. Prediabetic hyperamylinemia in humans promotes amylin oligomerization within the pancreatic secretory pathway and consequent secretion of oligomerized amylin
in the blood (amylin dyshomeostasis), which causes brain microhemorrhages leading to neuroinflammation and hypoxic-ischemic
brain injury. BBB, blood-brain barrier; 4HNE, 4 hydroxynonenal; MDA, malondialdehyde; IL-1β, interleukin 1β.
cline. Since some diabetes-associated factors (hyperglycemia,
insulin resistance) are also extending in non-diabetic populations, the association of diabetes with cognitive impairment
should also be studies in non-diabetic populations.
The link of diabetes with co-occurring disorders in the brain
involves complex and multifactorial pathways. Laboratory animals can help to better understand the relationship between
diabetes and cognitive impairments, which can further be used
to develop new treatment strategies to slow the progression of
pathological processes and cognitive decline. Since diabetesassociated amylin dyshomeostasis appears central to white
matter injury in AD [25], we propose that an appropriate combination of human amylin-expressing non-AD rats and AD
rats have the potential to uncover: (1) cellular and molecular
mechanisms that underlie the effects of amylin dyshomeostasis
on small blood vessels and white matter; (2) phenotypical
characteristics of the interaction between amylin dyshomeostasis and Aβ pathology; and (3) the interplay between mixed
VCID-AD and known amylin-mediated vascular injury [63].
Such knowledge is critical for designing novel interventions
based on our hypothesis of the central role of amylin dyshomeostasis in the development of mixed VCID-AD.
564
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